Online citations, reference lists, and bibliographies.
← Back to Search

The Effects Of Mianserin Hydrochloride On The Vascular Responses Evoked By 5-hydroxytryptamine And Related Vasoactive Substances.

P. Saxena, P. van Houwelingen, I. Bonta
Published 1971 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Among a few newly synthesized novel substituted piperazine derivatives, 2-methyl-1,2,3,4,10,14b-hexahydro-2H-pyrazino (1,2-f) morphanthridine hydrochloride (mianserin hydrochloride) was found to be a potent antagonist of some actions of 5-hydroxytryptamine (5-HT) and histamine. The present experiments were designed to study the effect of mianserin on some cardiovascular parameters in dogs and on the vascular responses of some physiologically occuring substances. Mainserin effectively antagonized the hypertensive, coronary vasodilator and venoconstrictor actions of 5-HT. In addition, the hypotensive action of histamine and the hypertensive action of catecholamines in dogs were partially antagonised by mianserin. Antagonism of noradrenaline-induced vasoconstriction was confirmed in the perfused central artery of the rabbit ear. However, in contrast to the above-mentioned anti 5-HT actions, mianserin enhanced the vasoconstrictor response to 5-HT in the external carotid bed of dogs indicating that the receptors for 5-HT in the carotid bed differ from those present in other vascular and non-vascular smooth muscles. It is argued that the possible effectiveness of such drugs in migraine may not be due to antagonism of the actions of 5-HT, but could possibly result from a potentiation of the latter's vasoconstrictor effect in the external carotid bed.
This paper references
10.1001/ARCHNEUR.1969.00480150053007
Monoamine oxidase inhibition in the treatment of migraine.
M. Anthony (1969)
10.1152/AJPLEGACY.1966.211.6.1424
Serotonin receptor in rabbit artery.
M. Wurzel (1966)
10.1152/AJPLEGACY.1959.197.4.736
Effect of serotonin (5-hydroxytryptamine) on the systemic and coronary vascular bed of the dog
G. Maxwell (1959)
10.3181/00379727-84-20612
Resistance Strain Gauge Arches for Direct Measurement of Heart Contractile Force in Animals.∗
K. Boniface (1953)
10.1021/JM00295A010
A noel type of substituted piperazine with high antiserotonin potency.
W. J. van der Burg (1970)
10.1016/0014-2999(71)90036-7
Mianserin hydrochloride: peripheral and central effects in relation to antagonism against 5-hydroxytryptamine and tryptamine.
B. Vargaftig (1971)
10.1001/ARCHNEURPSYC.1953.02320350003001
Studies on headache; long-term observations of the reactivity of the cranial arteries in subjects with vascular headache of the migraine type.
M. M. Tunis (1953)
10.1136/jnnp.27.5.463
Clinical trial of methysergide and other preparations in the management of migraine
D. A. Curran (1964)
10.1016/S0079-6468(08)70196-6
2 Pharmacological Aspects of the Coronary Circulation
J. R. Parratt (1969)
10.1016/0014-2999(70)90256-6
Ganglion-blocking, neuromuscular-blocking and other actions of 2-imino-4-ethyloxycarbonyl-1,3-diazacycloheptane hydrochloride (OG 30), a ganglionic stimulant.
P. Saxena (1970)
Studies in migraine.
Lance Jw (1966)
10.1001/ARCHNEUR.1961.00450090001001
Studies on headache. The mode of action of UML-491 and its relevance to the nature of vascular headache of the migraine type.
D. Dalessio (1961)
10.1177/000331976001100409
Clinical Observations with 1-Methyl-Lysergic Acid Butanolamide (Uml-491)* in Vascular Headache
A. Friedman (1960)
10.1159/000136014
Lack of evidence for M- and D-serotonin receptors in the cat's isolated tracheal smooth muscle.
P. Statkov (1969)
10.1093/BRAIN/88.5.997
Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects.
D. A. Curran (1965)
10.1159/000135851
Alpha and beta adrenergic receptors in human veins; activity of a new beta-blocking agent.
F. Sicuteri (1966)
10.7326/0003-4819-32-2-350_1
Headache and other head pain
H. Wolff (1972)
10.1159/000387441
Vasoneuroactive Substances and their Implication in Vascular Pain
F. Sicuteri (1967)
10.1159/000229055
Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine.
F. Sicuteri (1959)
10.1001/jama.1963.03710100133121
A SEROTONIN ANTAGONIST, CYPROHEPTADINE. II. THE TREATMENT OF VASCULAR-TYPE HEADACHE AND PRURITUS.
J. Miller (1963)
10.1002/cpt196344467
Systemic and coronary hemodynamic effects of an amine oxidase inhibitor and of serotonin
G. Rowe (1963)
10.1212/WNL.14.1.24
Cutaneous blood flow in vascular headaches of the migraine type
A. H. Elkind (1964)



This paper is referenced by
10.1111/j.1526-4610.1972.hed1202044.x
THE EFFECTS OF ANTIMIGRAINE DRUGS ON THE VASCULAR RESPONSES BY‐5‐HYDROXYTRYPTAMINE AND RELATED BIOGENIC SUBSTANCES ON THE EXTERNAL CAROTID BED OF DOGS: POSSIBLE PHARMACOLOGICAL IMPLICATIONS TO THEIR ANTIMIGRAINE ACTION
P. Saxena (1972)
10.1016/0014-2999(76)90249-1
On the mechanism of the coronary dilator effect of serotonin in the dog.
M. A. Mena (1976)
10.1016/0364-7722(80)90024-7
Cardiovascular effects of amitriptyline, mianserin and zimelidine in depressed patients
C. D. Burgess (1980)
10.1016/0278-5846(84)90140-4
Pharmacology of new antidepressants
B. Leonard (1984)
10.1007/BF01959033
Mianserin: result of a decade of antidepressant research
J. D. Ridder (2005)
10.1016/0014-2999(79)90230-9
Interaction of a potential antimigraine drug (Org GC 94) with the vasomotor action of serotonin.
J. Lamar (1979)
10.1136/pgmj.55.648.704
Cardiovascular effects of amitriptyline, mianserin, zimelidine and nomifensine in depressed patients.
C. D. Burgess (1979)
10.1016/0163-7258(94)00005-N
Serotonin receptors: subtypes, functional responses and therapeutic relevance.
P. Saxena (1995)
10.1111/j.2042-7158.1981.tb13739.x
An analysis of the mechanism of 5‐hydroxytrypt‐amine‐induced vasopressor responses in ganglion‐blocked anaesthetized dogs
W. Feniuk (1981)
10.2165/00003495-197816040-00001
Mianserin: A Review of its Pharmacological Properties and Therapeutic Efficacy in Depressive Illness
R. Brogden (2012)
10.1111/j.1476-5381.1985.tb12938.x
5‐Carboxamide tryptamine, a compound with high affinity for 5‐hydroxytryptamine! binding sites, dilates arterioles and constricts arteriovenous anastomoses
P. Saxena (1985)
10.1016/0014-2999(93)90539-T
Role of 5-HT1-like receptors in the increase in external carotid blood flow induced by 5-hydroxytryptamine in the dog.
C. Villalón (1993)
10.1007/978-3-642-66775-6_3
Basic Pharmacological Properties
E. Müller‐Schweinitzer (1978)
10.1007/BF00584089
Tissue blood flow and localization of arteriovenous anastomoses in pigs with microspheres of four different sizes
P. Saxena (2004)
10.1089/NEU.1991.8.193
Comparison of a serotonin antagonist, opioid antagonist, and TRH analog for the acute treatment of experimental spinal trauma.
M. Puniak (1991)
10.1016/0024-3205(78)90389-2
Plasma free 5-hydroxytryptamine (5-HT): evidence of an increase induced by LM 5008, a potent 5-HT uptake inhibitor.
A. Uzan (1978)
10.1111/j.1526-4610.1974.hed1304142.x
ROLE OF SOME BIOGENIC SUBSTANCES IN MIGRAINE AND RELEVANT MECHANISM IN ANTIMIGRAINE ACTION OF ERGOTAMINE‐STUDIES IN AN EXPERIMENTAL MODEL FOR MIGRAINE
Pramod R. Saxena (1974)
10.1016/0014-2999(77)90019-X
Effects of 5HT uptake inhibitors on the pressor response to 5HT in the pithed rat. The significance of the 5HT blocking property.
E. N. Petersen (1977)
What is a Witness Seminar
E. Tansey (1997)
10.1002/(SICI)1099-1077(199607)11:4<273::AID-HUP769>3.0.CO;2-E
Modulation by Mianserin Pretreatment of the Chronic Electroconvulsive Shock Effects on the Adrenergic System in the Cerebral Cortex of the Rat
I. Nalepa (1996)
10.1016/0028-3908(80)90198-7
Pharmacological properties of some “second generation” antidepressant drugs
B. Leonard (1980)
10.1038/272329a0
Brain histamine receptors as targets for antidepressant drugs
P. Kanof (1978)
5-Hydroxytryptamine Receptors Mediating Carotid and Systemic Haemodynamic Effects: The Relation to Acute Antimigraine Therapy
Peter de Vries (1999)
Novel Potential Antimigraine Compounds: Carotid and Systemic Haemodynamic Effects in a Porcine Model of Migraine
K. Kapoor (2003)
10.1007/BF01642904
5-HT in migraine — an introduction
P. Saxena (2004)
10.1016/0014-2999(78)90253-4
Regional and systemic haemodynamic changes evoked by 5-hydroxytryptamine in awake and anaesthetized rabbits.
P. Saxena (1978)
10.1016/B978-0-08-023195-2.50015-3
Pharmacological Spectrum of Some New Antidepressants
J. Maj (1979)
10.1016/0014-2999(75)90101-6
Analysis of ergotamine — 5-HT interaction on the isolated rat stomach preparation
Abraham L. Franhuijzen (1975)
10.1111/j.1749-6632.1979.tb56552.x
USE OF GENETICALLY DYSTROPHIC ANIMALS IN CHEMOTHERAPY TRIALS AND APPLICATION OF SEROTONIN ANTAGONISTS AS ANTIDYSTROPHIC DRUGS *
E. Barnard (1979)
10.1161/01.RES.60.3.309
Nonadrenergic neural vasodilator mechanisms.
J. Bevan (1987)
10.1111/j.1472-8206.1989.tb00455.x
CARDIOVASCULAR EFFECTS FROM STIMULATION OF 5‐HYDROXYTRYPTAMINE RECEPTORS
P. Saxena (1989)
10.1007/BF00422415
Changes in action of tricyclic and tetracyclic antidepressants: Desipramine and mianserin, on avoidance behavior in the course of the chronic treatment
J. Hano (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar